In an unconventional push to expand coverage for weight loss medications, Eli Lilly representatives recently visited the New Jersey State Policemen’s Benevolent Association to promote their drug Zepbound with a goal to convince that organization of the long-term cost savings associated with obesity treatment, The Wall Street Journal reported Nov. 19.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
